Partho Sen
Machine Learning, Biomarker Discovery, R (Programming Language), Python (Programming Language), MATLAB, Snakemake, High Performance Computing (HPC), Computational Biology, Bioinformatics, Mathematical Modeling,
Statistical Modeling, Statistical Data Analysis, Metabolomics, Single Cell Sequencing, Functional Genomics, Transcriptomics, Metagenomics, NGS, Proteomics, Human Genetics.
I've a 13-year background in computational biology and bioinformatics. My professional / research journey has been marked to unravel the intricacies of molecular signatures and processes in humans and microbes.
Currently specializing in precision and systems medicine, my focus centers on multiple myeloma and other cancer types. By utilization of multiomics (genomics, transcriptomics, proteomics and metabolomics) and clinical datasets, I tend to delineate cellular signatures and pathways associated with cancer, contributing to the biomarker discovery, and thereby attributing towards the cancer treatment.
My prior research has delved into diverse health conditions, including Diabetes (Type 1 & 2), Non-Alcoholic Fatty Liver Disease (NAFLD), Obesity, and Cardiovascular disease (Atherosclerosis). The overarching objective of my work is to identify molecular markers that serve as key insights into disease mechanisms and underlying pathways. Thereby, aim to formulate innovative drugs, inhibitors, and therapeutic strategies.
In addition to my proficiency in mathematical, statistical modeling and data science, I am an accomplished computer programmer; well-versed in machine learning. My passion lies in harnessing large datasets to design tools and methods that address contemporary challenges in healthcare, as well as cell and tissue biology.
I am confident that with my expertise, we can achieve significant breakthroughs in understanding and treating diseases that have hitherto posed significant challenges.
- Microbiome-derived bile acid signatures in early life and their association with islet autoimmunity (2026)
- Nature Communications
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Dynamics of gut metabolome and microbiota maturation during early life (2025)
- iScience
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Dysregulation of Microbiota in Patients With First-Episode Psychosis Is Associated With Symptom Severity and Treatment Response (2024)
- Biological Psychiatry
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Exposure to environmental toxicants is associated with gut microbiome dysbiosis, insulin resistance and obesity (2024)
- Environment International
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis (2024)
- Cell Reports Medicine
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Long noncoding RNA LIRIL2R modulates FOXP3 levels and suppressive function of human CD4+ regulatory T cells by regulating IL2RA (2024)
- Proceedings of the National Academy of Sciences of the United States of America
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Circulating metabolic signatures of rapid and slow progression to type 1 diabetes in islet autoantibody-positive children (2023)
- Frontiers in Endocrinology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Deep learning facilitates multi-data type analysis and predictive biomarker discovery in cancer precision medicine (2023)
- Computational and Structural Biotechnology Journal
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Use of big data from health insurance for assessment of cardiovascular outcomes (2023)
- Frontiers in Artificial Intelligence
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Dysregulation of secondary bile acid metabolism precedes islet autoimmunity and type 1 diabetes (2022)
- Cell Reports Medicine
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )



